ABSTRACT
Infection of toxoplasma gondii (TG), an intracellular neurotropic parasitic protozoon, has been associated with various neuropsychiatric disorders. TG is usually diagnosed from serological sample in which a positive test for Anti-TG immunoglobulin G (IgG) indicates TG infection (toxoplasmosis). The research was conducted to test the hypothesis that TG infection may be associated with substance abuse. Anti-TG (IgG) was screened in 444 participants (350 abusers and 94 controls) who attended the Psychiatry Department of Mansoura University Hospitals. All participants were screened for different class of abused substances (tramadol, cannabis, opiates, barbiturates and benzodiazepines) using enzyme multiplied immunoassay technique and positive cases were confirmed using gas chromatography-mass spectroscopy (GC-MS). Substance users were also diagnosed according to DSM IV criteria. GC-MS assays revealed that 116 cases (33.1% of users) had documented use of more than one substance. Tramadol was the most common abused substance [86 cases (24.6%)]. About 56% of the participants were sero-positive for anti-TG IgG. Toxoplasmosis sero-positivity was significantly higher among substance abusers (P < 0.0001) irrespective of the class of substance used. There was a significant relationship between toxoplasma sero-positivity and occurrence of convulsions among tramadol users (P = 0.0007) and those relapsing (P < 0.0001) following short periods of abstinence. The data collected suggest that TG infection is significantly associated with the high incidence of substance use, irrespective of the drug class. These preliminary findings warrant further larger multicenter clinical studies to test the robustness of this association.
ABSTRACT
BACKGROUND: Antipsychotic drugs (APs) are widely prescribed in psychiatry primarily for the treatment of psychosis in schizophrenia and bipolar disorders. An issue related to poor prognosis in patients with chronic illness relates to the accumulation of lactate levels in blood, leading to patients that become critically ill. It is suggested that haloperidol and olanzapine, as common therapy for schizophrenia, are associated with increased levels of blood lactate, which may contribute towards the extra-pyramidal side effects. AIMS AND METHOD: In this study, 88 patients attending the psychiatry outpatient clinic of Mansoura University Hospital, under treatment with typical APs (chlorpromazine or haloperidol) or the atypical APs (risperidone, olanzapine or quetiapine) were followed over a three-month period. Blood lactate levels were assessed at diagnosis, ten days and 90 days after the start of AP treatment. Extra-pyramidal symptoms (EPSs) were studied in participants during the course of this study. RESULTS: Chlorpromazine and haloperidol caused significant increases in lactate levels within the first ten days of therapy, while after 90 days, all APs showed significant increases in arterial blood lactate levels in comparison with the first baseline measurement (for all APs, p-values <0.0001). Dystonia was reported by patients on chlorpromazine, haloperidol and risperidone therapies, while Parkinsonian-like manifestations were reported with all APs tested except for quetiapine. Both dystonia and Parkinsonian-like manifestations were also observed alongside the significant increases in arterial blood lactate levels in comparison to patients on therapy not displaying EPSs. CONCLUSION: These findings suggest elevated blood lactate levels may serve as early biomarkers for occurrence of extra-pyramidal symptoms in patients on chronic APs treatment.